secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHAMPIONS ONCOLOGY, INC. (CSBR)
CIK:        0000771856
Form:       8-K
Filed at:   2022-03-15T23:59:59+00:00
Accession:  0001628280-22-006255
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Champions Oncology Q3 revenue record $13.2M, up 22% YoY; adj. EBITDA $1.5M
--------------------------------------------------------------------------

- Revenue of $13.2M for quarter ended Jan 31, 2022, a 22% increase from $10.8M in prior year.
- Adjusted EBITDA was $1.5M; net income from operations of $830K (incl. $310K stock comp).
- Gross margin for Q3 was 51.4% vs 57.2% a year ago; nine-month gross margin improved to 51.9% from 48.8%.
- Cash position $8.7M with no debt; signed co-development partnerships with Fannin Innovation Studio and Gigamune.
- Company reaffirms FY2022 revenue growth guidance of 15%-20%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/771856/000162828022006255/0001628280-22-006255-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/771856/000162828022006255/csbr-20220315.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-006255

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer